Observation on the efficacy of brigatinib/brigatinib in the treatment of brain metastases

Brigatinib/Brigatinib (Brigatinib) is an innovative oral targeted drug designed for the treatment of ALK (anaplastic lymphoma kinase)-positive non-small cell lung cancer. Its unique mechanism lies in inhibiting the growth and spread of tumors by inhibiting the activity of ALK protein. Recent studies have shown that brigatinib has significant results in the treatment of this type of lung cancer. Especially for patients who are ineffective or failed with other treatments, brigatinib has demonstrated significant tumor suppression effects and effectively prolonged the progression-free survival of patients.

Brigatinib has the ability to cross the blood-brain barrier, which gives it unique advantages in the treatment of brain metastases. For patients with ALK fusion gene-positive lung cancer, brain metastasis is a common complication. Fortunately, brigatinib can pass through the blood-brain barrier and exert a therapeutic effect on lesions of the central nervous system.

A clinical case shows that a patient in his 50s with stage IV pleural metastases unfortunately developed brain metastases after taking crizotinib for 10 years. However, after switching to brigatinib, his condition went into complete remission. Another patient in his early 60s suffered stage III recurrent large-area brain metastasis after undergoing radiotherapy and chemotherapy for 5 years. However, after taking brigatinib, his tumor shrank significantly. These cases fully prove the efficacy and good tolerability of brigatinib in the treatment of ALK fusion gene-positive lung cancer brain metastases.

Each patient's response to treatment medications is unique. Although brigatinib is effective, it may also cause some side effects, such as nausea, vomiting, diarrhea, fatigue, and rash. Therefore, before initiating brigatinib treatment, doctors will thoroughly evaluate the patient's specific condition and overall health to ensure that the effectiveness of the treatment is maximized while minimizing potential risks.